Kevin J. Filipski
Pfizer (United States)(US)
Publications by Year
Research Areas
Pancreatic function and diabetes, Diabetes Treatment and Management, Metabolism, Diabetes, and Cancer, Blood Coagulation and Thrombosis Mechanisms, Biochemical and Molecular Research
Most-Cited Works
- → Discovery of (S)-6-(3-Cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic Acid as a Hepatoselective Glucokinase Activator Clinical Candidate for Treating Type 2 Diabetes Mellitus(2011)115 cited
- → Pyridones as glucokinase activators: Identification of a unique metabolic liability of the 4-sulfonyl-2-pyridone heterocycle(2009)80 cited
- → Designing glucokinase activators with reduced hypoglycemia risk: discovery of N,N-dimethyl-5-(2-methyl-6-((5-methylpyrazin-2-yl)-carbamoyl)benzofuran-4-yloxy)pyrimidine-2-carboxamide as a clinical candidate for the treatment of type 2 diabetes mellitus(2011)68 cited
- → A versatile copper-catalyzed coupling reaction of pyridin-2(1H)-ones with aryl halides(2006)56 cited
- → Intestinal Targeting of Drugs: Rational Design Approaches and Challenges(2013)54 cited
- → Novel and selective spiroindoline-based inhibitors of sky kinase(2011)48 cited
- → The design and synthesis of indazole and pyrazolopyridine based glucokinase activators for the treatment of Type 2 diabetes mellitus(2012)44 cited
- → The design and synthesis of a potent glucagon receptor antagonist with favorable physicochemical and pharmacokinetic properties as a candidate for the treatment of type 2 diabetes mellitus(2013)40 cited
- → The Discovery of (2R,4R)‐N‐(4‐chlorophenyl)‐N‐ (2‐fluoro‐4‐(2‐oxopyridin‐1(2H)‐yl)phenyl)‐4‐methoxypyrrolidine‐1,2‐dicarboxamide (PD 0348292), an Orally Efficacious Factor Xa Inhibitor(2007)39 cited
- → Selective pharmacological inhibition of the sodium-dependent phosphate cotransporter NPT2a promotes phosphate excretion(2020)38 cited